LV12150B - Inhibitors of farnesyl protein transferase - Google Patents

Inhibitors of farnesyl protein transferase Download PDF

Info

Publication number
LV12150B
LV12150B LVP-98-129A LV980129A LV12150B LV 12150 B LV12150 B LV 12150B LV 980129 A LV980129 A LV 980129A LV 12150 B LV12150 B LV 12150B
Authority
LV
Latvia
Prior art keywords
tetrahydro
imidazol
ylmethyl
benzodiazepine
phenyl
Prior art date
Application number
LVP-98-129A
Other languages
English (en)
Latvian (lv)
Other versions
LV12150A (lv
Inventor
Charles Z. Ding
John T. Hunt
Soong-Hoon Kim
Toomas Mitt
Raheev Bhide
Katerina Leftheris
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26683350&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12150(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LV12150A publication Critical patent/LV12150A/xx
Publication of LV12150B publication Critical patent/LV12150B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
LVP-98-129A 1996-02-26 1998-06-04 Inhibitors of farnesyl protein transferase LV12150B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1226596P 1996-02-26 1996-02-26
US2280596P 1996-07-25 1996-07-25
PCT/US1997/002920 WO1997030992A1 (en) 1996-02-26 1997-02-24 Inhibitors of farnesyl protein transferase

Publications (2)

Publication Number Publication Date
LV12150A LV12150A (lv) 1998-10-20
LV12150B true LV12150B (en) 1998-12-20

Family

ID=26683350

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-98-129A LV12150B (en) 1996-02-26 1998-06-04 Inhibitors of farnesyl protein transferase

Country Status (24)

Country Link
US (2) US6011029A (de)
EP (2) EP0892797A4 (de)
JP (1) JP4115529B2 (de)
KR (1) KR100522983B1 (de)
CN (2) CN100376569C (de)
AU (1) AU718676B2 (de)
BG (1) BG64951B1 (de)
BR (1) BR9707614A (de)
CA (1) CA2239187C (de)
CZ (1) CZ299762B6 (de)
EE (1) EE04309B1 (de)
GE (1) GEP20022616B (de)
HU (1) HUP9902016A3 (de)
IL (2) IL124197A (de)
LV (1) LV12150B (de)
NO (1) NO319395B1 (de)
NZ (1) NZ330287A (de)
PL (1) PL191502B1 (de)
RO (1) RO121118B1 (de)
RU (1) RU2225405C2 (de)
SK (1) SK286568B6 (de)
TW (1) TW496863B (de)
UA (1) UA52642C2 (de)
WO (1) WO1997030992A1 (de)

Families Citing this family (188)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117641A (en) 1996-04-11 2000-09-12 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents and uses related thereto
US6727082B1 (en) 1996-04-11 2004-04-27 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
JP2001513622A (ja) 1996-04-11 2001-09-04 マイトティックス インコーポレーテッド 抗菌剤の同定のためのアッセイおよび試薬、並びにそれらに関連する利用
AU709409B2 (en) * 1996-07-15 1999-08-26 Bristol-Myers Squibb Company Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
WO1999010525A1 (en) * 1997-08-27 1999-03-04 Merck & Co., Inc. A method of treating cancer
CA2304473A1 (en) * 1997-09-29 1999-04-22 Rajeev S. Bhide Inhibitors of farnesyl protein transferase
US6458783B1 (en) * 1997-09-29 2002-10-01 Bristol-Myers Squibb Company Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
EP1049664B1 (de) * 1997-12-22 2005-03-16 Bayer Pharmaceuticals Corporation Hemmung der raf-kinase unter verwendung von symmetrisch und unsymmetrisch substituierten harnstoffen
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US6071903A (en) * 1998-01-27 2000-06-06 American Cyanamid Company 2,3,4,5-tetrahydro-1H-[1,4]-benzodiazepine-3-hydroxyamic acids
US6423519B1 (en) * 1998-07-15 2002-07-23 Gpc Biotech Inc. Compositions and methods for inhibiting fungal growth
US6316436B1 (en) 1998-12-08 2001-11-13 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
US6284755B1 (en) 1998-12-08 2001-09-04 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1140840B1 (de) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (en) 1999-01-13 2013-10-08 Bayer Healthcare Llc .omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359646C (en) * 1999-01-21 2008-12-02 Bristol-Myers Squibb Company Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-.beta.-cyclodextrin or 2-hydroxypropyl-.beta.-cyclodextrin and method
CA2363169A1 (en) * 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
NZ513639A (en) 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20020115696A1 (en) 1999-06-18 2002-08-22 Yoel Kloog Treatment of post-angioplasty restenosis and atherosclerosis with ras antagonists
EP1187605A4 (de) * 1999-06-18 2004-05-26 Thyreos Corp BEHANDLUNG DER NICHT BöSARTIGEN KRANKHEITEN MIT RAS-ANTAGONISTEN
US7034055B1 (en) 1999-06-30 2006-04-25 Prescient Neuropharma Inc. 2-aminoindane analogs
FR2796943A1 (fr) * 1999-07-30 2001-02-02 Aventis Pharma Sa Derives de benzoxazinnes, leur procede de preparation et leur utilisation en therapeutique
EP1088821A1 (de) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksamer Sulfonamid Derivate
US6100395A (en) * 2000-01-10 2000-08-08 Bristol-Myers Squibb Company Reductive alkylation of secondary amines with hydrosilane
US6838467B2 (en) 2000-02-24 2005-01-04 Janssen Pharmaceutica N. V. Dosing regimen
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
EP1283055A4 (de) * 2000-04-07 2003-05-07 Takeda Chemical Industries Ltd Lösliche promotoren der sekretion von beta amyloid protein vorläufer
DE60139080D1 (de) * 2000-11-21 2009-08-06 Janssen Pharmaceutica Nv Farnesyltransferase hemmende benzoheterocyclische derivate
WO2002043733A1 (en) * 2000-11-28 2002-06-06 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
US20040067968A1 (en) * 2000-12-27 2004-04-08 Angibaud Patrick Rene Farnesyl transferase inhibiting 4-heterocyclyl quinoline and quinazoline
WO2002051835A1 (en) * 2000-12-27 2002-07-04 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
AU2002236813A1 (en) * 2001-01-22 2002-07-30 Schering Corporation Treatment of malaria with farnesyl protein transferase inhibitors
CZ20032021A3 (cs) 2001-01-25 2004-05-12 Bristol@Myersásquibbácompany Způsoby podávání analogů epothilonu při léčbě rakoviny
US7371763B2 (en) 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
US7759323B2 (en) 2001-05-22 2010-07-20 Eisai R & D Management Co., Ltd. Highly purified antiendotoxin compound
US6905813B2 (en) * 2001-08-29 2005-06-14 Chugai Photo Chemical Co., Ltd. Processing agent for silver halide color photosensitive material and processing method thereof
US20030134846A1 (en) * 2001-10-09 2003-07-17 Schering Corporation Treatment of trypanosoma brucei with farnesyl protein transferase inhibitors
US7074921B2 (en) * 2001-11-13 2006-07-11 Bristol Myers Squibb Company Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds
EP2324825A1 (de) 2002-02-11 2011-05-25 Bayer Healthcare LLC Arylharnstoffe mit Angiogenese hemmender Aktivität
SI1580188T1 (sl) 2002-02-11 2012-02-29 Bayer Healthcare Llc Aril sečnine kot kinazni inhibitorji
AU2003214110A1 (en) * 2002-03-15 2003-09-29 Ciba Specialty Chemicals Holding Inc. 4-aminopyrimidines and their use for the antimicrobial treatment of surfaces
US7405234B2 (en) * 2002-05-17 2008-07-29 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
US20060106102A1 (en) * 2002-06-07 2006-05-18 Eric Morand Napththalene derivatives which inhibit the cytokine or biological activity of microphage migration inhibitory factor (mif)
WO2003106628A2 (en) * 2002-06-17 2003-12-24 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f1f0 atp hydrolase and methods of inhibiting f1f0 atp hydrolase
EP1534862A4 (de) * 2002-08-07 2007-10-10 Exelixis Inc Modulatoren von rabggt und verfahren zu deren verwendung
EP1567487A4 (de) * 2002-11-15 2005-11-16 Bristol Myers Squibb Co Offenkettige, mit prolylharnstoff verwandtemodulatoren der androgenrezeptorfunktion
JP2004346059A (ja) * 2003-01-28 2004-12-09 Takeda Chem Ind Ltd 受容体作動薬
CA2514547A1 (en) * 2003-01-28 2004-08-12 Takeda Pharmaceutical Company Limited Receptor agonists
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
DE602004007382T2 (de) 2003-05-20 2008-04-17 Bayer Pharmaceuticals Corp., West Haven Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da) 2003-07-23 2008-04-07 Bayer Pharmaceuticals Corp Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
US7417026B2 (en) 2003-08-13 2008-08-26 Children's Hospital Medical Center Mobilization of hematopoietic cells
JP2007535479A (ja) 2003-08-13 2007-12-06 チルドレンズ ホスピタル メディカル センター ＧＴＰａｓｅを調節するためのキメラペプチド
US7256208B2 (en) * 2003-11-13 2007-08-14 Bristol-Myers Squibb Company Monocyclic N-Aryl hydantoin modulators of androgen receptor function
JP4691041B2 (ja) 2003-11-20 2011-06-01 チルドレンズ ホスピタル メディカル センター Ｇｔｐアーゼ阻害剤および使用方法
US7820702B2 (en) 2004-02-04 2010-10-26 Bristol-Myers Squibb Company Sulfonylpyrrolidine modulators of androgen receptor function and method
US20050182105A1 (en) * 2004-02-04 2005-08-18 Nirschl Alexandra A. Method of using 3-cyano-4-arylpyridine derivatives as modulators of androgen receptor function
US7378426B2 (en) 2004-03-01 2008-05-27 Bristol-Myers Squibb Company Fused heterotricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
US7696241B2 (en) 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7388027B2 (en) * 2004-03-04 2008-06-17 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
US7625923B2 (en) 2004-03-04 2009-12-01 Bristol-Myers Squibb Company Bicyclic modulators of androgen receptor function
JP2007529555A (ja) * 2004-03-18 2007-10-25 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド シヌクレイノパチーを治療する方法
US20060106060A1 (en) * 2004-03-18 2006-05-18 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies (Lansbury)
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
EP1744751A4 (de) * 2004-03-18 2010-03-10 Brigham & Womens Hospital Verfahren zur behandlung von synucleinopathien
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
US7323455B2 (en) * 2004-03-24 2008-01-29 Wyeth 7-aryl 1,5-dihydro-4,1-benzoxazepin-2(3H)-one derivatives and their use as progesterone receptor modulators
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US10675326B2 (en) 2004-10-07 2020-06-09 The Board Of Trustees Of The University Of Illinois Compositions comprising cupredoxins for treating cancer
EP1815247B1 (de) 2004-11-05 2013-02-20 Janssen Pharmaceutica NV Therapeutische verwendung von farnesyltransferase-hemmern und verfahren zur überwachung der wirksamkeit
MX2007005763A (es) 2004-11-18 2007-07-20 Squibb Bristol Myers Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma.
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
CA2602351A1 (en) * 2005-03-25 2006-10-05 Kissei Pharmaceutical Co., Ltd. Urea derivative, medicinal composition containing the same, and medicinal use of these
US20060235006A1 (en) * 2005-04-13 2006-10-19 Lee Francis Y Combinations, methods and compositions for treating cancer
EP2527337A1 (de) * 2005-04-14 2012-11-28 Bristol-Myers Squibb Company Hemmer des 11-Beta-Hydroxysteroid-Dehydrogenase-1-Enzyms
WO2006135790A1 (en) * 2005-06-09 2006-12-21 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant kit protein
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2006275528B2 (en) 2005-07-29 2012-03-08 Children's Hospital Medical Center GTPase inhibitors and methods of use and crystal structure of Rac-1 GTPase
US7700592B2 (en) 2005-08-25 2010-04-20 Schering Corporation α2C adrenoreceptor agonists
ES2348997T3 (es) * 2005-08-25 2010-12-21 Schering Corporation Compuestos de 3,4-dihidro-2h-benzo[1,4]oxazina y 3,4-dihidro-2h-benzo[1,4]tiazina como agonistas del adrenorreceptor alfa2c.
PL1948607T3 (pl) 2005-09-16 2010-09-30 Janssen Pharmaceutica Nv Cyklopropyloaminy jako modulatory receptora histaminowego H3
US20090099197A1 (en) * 2005-11-15 2009-04-16 Bristol-Myers Squibb Company Methods of Identifying and Treating Individuals Exhibiting MDR-1 Overexpression With Protein Tyrosine Kinase Inhibitors and Combinations Thereof
AU2007215221C1 (en) * 2006-02-14 2013-05-30 Vertex Pharmaceuticals Incorporated Dihydrodiazepines useful as inhibitors of protein kinases
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
EP2016070B1 (de) 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitoren von c-fms-kinase
MX2008013533A (es) 2006-04-20 2009-01-15 Janssen Pharmaceutica Nv Compuestos heterociclicos como inhibidores de c-fms cinasa.
KR20090095626A (ko) 2006-12-04 2009-09-09 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 쿠프레독신과 ＣｐＧ 리치 ＤＮＡ를 이용한 조성물 및 암 치료 방법
LT2121636T (lt) 2006-12-14 2017-05-10 Janssen Pharmaceutica N.V. Piperazinilo ir diazepanilo benzamido darinių gamybos būdas
WO2008089135A2 (en) * 2007-01-12 2008-07-24 University Of South Florida Identification of biomarkers predictive of dasatinib effects in cancer cells
AU2008212788A1 (en) 2007-02-08 2008-08-14 The Board Of Trustees Of The University Of Illinois Compositions and methods to prevent cancer with cupredoxins
CA2685860A1 (en) * 2007-05-10 2008-11-20 Amr Technology, Inc. Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
WO2008144981A1 (en) 2007-05-25 2008-12-04 Topharman Shanghai Co., Ltd. Methods and intermediates for preparing 4-acetyl-2,3,4,5-tetrahydro-1h-1,4-benzodiazepine
AR068046A1 (es) 2007-06-05 2009-11-04 Schering Corp Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer
RU2341308C1 (ru) * 2007-08-09 2008-12-20 Государственное учреждение Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского (МОНИКИ им. М.Ф. Владимирского) Способ лечения нерезектабельного рака панкреатодуоденальной области
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
CA2708281A1 (en) 2007-12-11 2009-08-27 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitors using metal binding moieties in combination with targeting moieties
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
LT2303270T (lt) * 2008-05-05 2017-09-11 Sanofi Acilamino-pakeistieji sulieti ciklopentankarboksirūgšties dariniai ir jų panaudojimas kaip vaistų
WO2010014784A2 (en) 2008-08-01 2010-02-04 Bristol-Myers Squibb Company Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases
MX2011005096A (es) * 2008-11-13 2011-11-18 Link Medicine Corp Derivados de azaquinolinona y usos de los mismos.
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
CA2763008A1 (en) * 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
SG176628A1 (en) 2009-06-05 2012-01-30 Link Medicine Corp Aminopyrrolidinone derivatives and uses thereof
LT2769737T (lt) 2009-07-20 2017-06-26 Bristol-Myers Squibb Company Anti-ctla4 antikūno derinys su etopozidu, skirtas sinerginiam proliferacinių ligų gydymui
JP2013506669A (ja) 2009-09-30 2013-02-28 メルク・シャープ・アンド・ドーム・コーポレーション Ｅｒｋ阻害剤である新規化合物
EP2501387B1 (de) 2009-11-17 2016-07-27 The Regents Of The University Of Michigan 1,4-benzodiazepin-2,5-dione und verbindungen daraus mit therapeutischen eigenschaften
WO2011125568A1 (ja) * 2010-04-06 2011-10-13 日本曹達株式会社 含窒素複素環化合物及びその製造方法
AU2014201037B9 (en) * 2010-04-06 2015-11-19 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and method for producing same
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
EP2654748B1 (de) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
BR112013018534B1 (pt) 2011-01-20 2021-04-06 Board Of Regents, The University Of Texas System Agente de contraste, seus métodos de preparação, e produto de combinação
CN102863474A (zh) 2011-07-09 2013-01-09 陈小平 一类治疗细胞增殖性疾病的铂化合物、其制备方法和应用
CN102993239A (zh) 2011-09-19 2013-03-27 陈小平 离去基团含氨基或烷胺基的丁二酸衍生物的铂类化合物
WO2013064231A1 (en) 2011-10-31 2013-05-10 Phenex Pharmaceuticals Ag SEVEN-MEMBERED SULFONAMIDES AS MODULATORS OF RAR-RELATED ORPHAN RECEPTOR-GAMMA (RORγ, NR1F3)
US9980942B2 (en) 2012-05-02 2018-05-29 Children's Hospital Medical Center Rejuvenation of precursor cells
JP6306585B2 (ja) 2012-07-31 2018-04-04 ダウ グローバル テクノロジーズ エルエルシー オレフィン重合触媒活性化剤を製造する方法
CN104870454B (zh) 2012-08-07 2020-03-03 詹森药业有限公司 用于制备杂环酯衍生物的方法
CN107266405A (zh) 2012-08-07 2017-10-20 詹森药业有限公司 用于制备c‑fms激酶抑制剂的方法
WO2014075391A1 (zh) 2012-11-17 2014-05-22 北京市丰硕维康技术开发有限责任公司 离去基团是含氨基或烷氨基的丙二酸衍生物的铂类化合物
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
TW201524952A (zh) * 2013-03-15 2015-07-01 Araxes Pharma Llc Ｋｒａｓ ｇ１２ｃ之共價抑制劑
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
US10028503B2 (en) 2014-06-18 2018-07-24 Children's Hospital Medical Center Platelet storage methods and compositions for same
KR20170020527A (ko) 2014-06-27 2017-02-22 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 배양된 포유동물 윤부 줄기세포, 이를 생성하는 방법, 및 이의 용도
MX382355B (es) 2015-04-10 2025-03-13 Araxes Pharma Llc Compuestos de quinazolina sustituidos y métodos de uso de los mismos.
EP3283462B1 (de) 2015-04-15 2020-12-02 Araxes Pharma LLC Kondensierte tricyclische inhibitoren von kras und anwendungsverfahren dafür
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EA201890512A1 (ru) 2015-08-17 2018-09-28 Кура Онколоджи, Инк. Способы лечения пациентов со злокачественными опухолями с использованием ингибиторов фарнезилтрансферазы
EP3356351A1 (de) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
EP3356349A1 (de) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
WO2017058792A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356354A1 (de) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356347A1 (de) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
EP3377481A1 (de) 2015-11-16 2018-09-26 Araxes Pharma LLC 2-substituierte chinazolinverbindungen mit einer substituierten heterocyclischen gruppe und verfahren zur verwendung davon
WO2017184968A1 (en) 2016-04-22 2017-10-26 Kura Oncology, Inc. Methods of selecting cancer patients for treatment with farnesyltransferase inhibitors
WO2017205536A2 (en) * 2016-05-24 2017-11-30 Genentech, Inc. Therapeutic compounds and uses thereof
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
EP3519402A1 (de) 2016-09-29 2019-08-07 Araxes Pharma LLC Inhibitoren von kras-g12c-mutanten proteinen
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
RS61745B1 (sr) 2016-11-03 2021-05-31 Kura Oncology Inc Inhibitori farneziltransferaze za upotrebu u tretiranju kancera
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
EP3573954A1 (de) 2017-01-26 2019-12-04 Araxes Pharma LLC Fusionierte bicyclische benzoheteroaromatische verbindungen und verfahren zur verwendung davon
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US10137121B2 (en) 2017-02-21 2018-11-27 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
KR102003179B1 (ko) 2017-02-21 2019-07-23 쿠라 온콜로지, 인크. 파르네실트랜스퍼라제 억제제를 사용하는 암 환자의 치료 방법
CN110831933A (zh) 2017-05-25 2020-02-21 亚瑞克西斯制药公司 喹唑啉衍生物作为突变kras、hras或nras的调节剂
JP2020521741A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー がんの処置のための化合物およびその使用の方法
CN110869358A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 Kras的共价抑制剂
US10806730B2 (en) 2017-08-07 2020-10-20 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
MX2020001207A (es) 2017-08-07 2020-03-20 Kura Oncology Inc Metodos de tratamiento del cancer con inhibidores de farnesiltransferasa.
WO2019055877A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
KR20250067962A (ko) 2018-06-29 2025-05-15 포르마 세라퓨틱스 인크. Creb 결합 단백질(cbp)의 저해
BR112021001709A2 (pt) 2018-08-01 2021-05-04 Araxes Pharma Llc compostos espiro heterocíclicos e métodos de uso dos mesmos para o tratamento de câncer
UY38427A (es) 2018-10-26 2020-05-29 Novartis Ag Métodos y composiciones para terapia con células oculares
EP3873469A2 (de) 2018-11-01 2021-09-08 Kura Oncology, Inc. Verfahren zur behandlung von krebs mit farnesyltransferase-inhibitoren
US20220071941A1 (en) 2018-12-21 2022-03-10 Kura Oncology, Inc. Therapies for squamous cell carcinomas
WO2020180663A1 (en) 2019-03-01 2020-09-10 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US12351577B2 (en) 2019-03-15 2025-07-08 Forma Therapeutics, Inc. Inhibiting cyclic AMP-responsive element-binding protein (CREB)
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
SG11202110472WA (en) 2019-03-29 2021-10-28 Kura Oncology Inc Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
US20220168296A1 (en) 2019-04-01 2022-06-02 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
US20220305001A1 (en) 2019-05-02 2022-09-29 Kura Oncology, Inc. Methods of treating acute myeloid leukemia with farnesyltransferase inhibitors
EP3972978A4 (de) * 2019-05-20 2023-04-26 California Institute Of Technology Kras-g12c-inhibitoren und ihre verwendungen
EP4013402B1 (de) 2019-08-16 2024-11-06 Children's Hospital Medical Center Cdc-42-inhibitoren zur verwendung bei der behandlung von altersverbundener depression, sarkopenie oder gebrechlichkeit
US20230348852A1 (en) 2020-04-27 2023-11-02 Novartis Ag Methods and compositions for ocular cell therapy
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)
WO2022231927A1 (en) * 2021-04-27 2022-11-03 Merck Sharp & Dohme Llc Phenyl azepines as ripk1 inhibitors and methods of use thereof
US20220409554A1 (en) * 2021-06-14 2022-12-29 IC-MedTech Corp. Ascorbic acid and quinone compound for cancer treatment
CN115745960B (zh) * 2021-09-02 2024-08-30 中国科学院上海药物研究所 一类含喹啉酮酰胺的化合物及其制备方法、药物组合物和用途
CN114230529A (zh) * 2021-11-03 2022-03-25 河南大学 四氢喹喔啉磺酰胺衍生物及其制备方法与用途
WO2023143389A1 (zh) * 2022-01-29 2023-08-03 江苏恒瑞医药股份有限公司 稠杂环类化合物、其制备方法及其在医药上的应用
EP4612146A1 (de) * 2022-10-31 2025-09-10 Eli Lilly and Company Ahr-agonisten
WO2026024795A1 (en) * 2024-07-24 2026-01-29 Lucy Therapeutics, Inc. F-atp hydrolase inhibitors

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1923821A1 (de) * 1969-05-09 1970-11-19 Wuelfing J A Fa 1,2,4,5-Tetrahydro-[3H]-benzo-1,4-diazepin-2,5-dion-Derivate,Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneipraeparaten
JPS6168487A (ja) * 1984-09-12 1986-04-08 Sumitomo Chem Co Ltd カルバモイルアゾール誘導体およびそれを有効成分とする除草剤
SU1528319A3 (ru) * 1985-07-23 1989-12-07 Глэксо Груп Лимитед (Фирма) Способ получени производных имидазола или их физиологически приемлемых солей
EP0322779A3 (de) * 1987-12-29 1991-05-08 Yoshitomi Pharmaceutical Industries, Ltd. Benzolaktam-Verbindungen und deren pharmazeutische Verwendungen
DE4010797A1 (de) * 1990-04-04 1991-10-10 Hoechst Ag Substituierte azole, verfahren zu deren herstellung, diese enthaltende mittel und deren verwendung
JP2729545B2 (ja) 1991-06-05 1998-03-18 富士写真フイルム株式会社 ハロゲン化銀カラー写真感光材料用の処理液及びそれを用いた処理方法
US5352705A (en) * 1992-06-26 1994-10-04 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
SG63579A1 (en) * 1992-12-21 1999-03-30 Smithkline Beecham Corp Bicyclic fibrinogen antagonists
AU6219994A (en) * 1993-03-11 1994-09-26 Yamanouchi Pharmaceutical Co., Ltd. Compound with vasopressin antagonism
CA2118985A1 (en) * 1993-04-02 1994-10-03 Dinesh V. Patel Heterocyclic inhibitors of farnesyl protein transferase
US5441952A (en) * 1993-04-05 1995-08-15 Merck & Co., Inc. Fibrinogen receptor antagonists
WO1994026723A2 (en) 1993-05-14 1994-11-24 Genentech, Inc. ras FARNESYL TRANSFERASE INHIBITORS
WO1995012612A1 (en) * 1993-11-05 1995-05-11 Warner-Lambert Company Substituted di- and tripeptide inhibitors of protein:farnesyl transferase
US5753650A (en) * 1994-05-20 1998-05-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
AU702661B2 (en) * 1994-06-29 1999-02-25 Smithkline Beecham Corporation Vitronectin receptor antagonists
US5977101A (en) * 1995-06-29 1999-11-02 Smithkline Beecham Corporation Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity
US6362191B1 (en) 1997-08-29 2002-03-26 Zeneca Ltd. Aminometyl oxooxazolidinyl benzene derivatives

Also Published As

Publication number Publication date
BR9707614A (pt) 1999-07-27
HUP9902016A3 (en) 2000-02-28
KR100522983B1 (ko) 2006-09-20
CA2239187C (en) 2003-04-22
LV12150A (lv) 1998-10-20
JP2000502356A (ja) 2000-02-29
CZ299762B6 (cs) 2008-11-12
CN100376569C (zh) 2008-03-26
EE04309B1 (et) 2004-06-15
BG64951B1 (bg) 2006-10-31
IL124197A (en) 2003-06-24
IL141908A0 (en) 2002-03-10
GEP20022616B (en) 2002-01-25
US6455523B1 (en) 2002-09-24
NO983892L (no) 1998-08-25
CZ269698A3 (cs) 1999-10-13
PL191502B1 (pl) 2006-05-31
WO1997030992A1 (en) 1997-08-28
SK286568B6 (sk) 2009-01-07
SK117398A3 (en) 2000-12-11
NO983892D0 (no) 1998-08-25
CA2239187A1 (en) 1997-08-28
EE9800262A (et) 1999-02-15
AU718676B2 (en) 2000-04-20
CN1347881A (zh) 2002-05-08
UA52642C2 (uk) 2003-01-15
TW496863B (en) 2002-08-01
IL141908A (en) 2003-04-10
EP1481975A1 (de) 2004-12-01
EP0892797A1 (de) 1999-01-27
RO121118B1 (ro) 2006-12-29
CN1214685A (zh) 1999-04-21
NZ330287A (en) 2000-03-27
RU2225405C2 (ru) 2004-03-10
HUP9902016A2 (hu) 1999-09-28
PL328868A1 (en) 1999-03-01
BG102738A (en) 1999-09-30
US6011029A (en) 2000-01-04
EP0892797A4 (de) 2004-10-20
JP4115529B2 (ja) 2008-07-09
KR19990087250A (ko) 1999-12-15
AU2136697A (en) 1997-09-10
NO319395B1 (no) 2005-08-08

Similar Documents

Publication Publication Date Title
AU718676B2 (en) Inhibitors of farnesyl protein transferase
AU735366B2 (en) Inhibitors of farnesyl protein transferase
AU734721B2 (en) Inhibitors of farnesyl protein transferase
US10053431B2 (en) Tetrahydro-benzodiazepinones
WO1998002436A1 (en) Thiadioxobenzodiazepine inhibitors of farnesyl protein transferase
US6458783B1 (en) Non-imidazole benzodiazepine inhibitors of farnesyl protein transferase
US20030162965A1 (en) Process for the preparation of 3,7-disubstituted-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine compounds
HK1070890A (en) Inhibitors of farnesyl protein transferase
LT4552B (lt) Farnezilproteintransferazės inhibitoriai